Magnum (Investment) Pharmaceutical Corporation Limited

Yes. Magnum (Investment) Pharmaceutical Corporation Limited is a legitimate Hong Kong corporation (Private company limited by shares) duly incorporated under the Companies Ordinance (Cap. 622) on 2019-06-20 (operating for 7 years). According to official registers of the Hong Kong Companies Registry (CR), the entity holds an active statutory standing of [Live / In Operation], possessing independent legal personality and full corporate capacity (Statutory verification: June 2019).

The statutory primary identifiers for Magnum (Investment) Pharmaceutical Corporation Limited are: 1. Business Registration Number (BRN / Unique Business Identifier UBI): [70859556] (effective from 27 December 2023, this 8-digit number issued under Cap. 310 serves as the unified cross-departmental corporate identifier); 2. Company Registration Number (CRN): [2843147] (incorporation archive number issued under Cap. 622). Together, these dual keys uniquely lock the entity in international banking KYC and cross-border contracts.

Under the Companies Ordinance (Cap. 622) of Hong Kong, incorporated companies do not maintain a single 'legal representative' position; the Board of Directors (Section 643) exercises statutory management authority. Under the New Inspection Regime, public inspection displays directors' correspondence addresses and partially masked identification numbers. Complete current and historical directorships (Form ND2A), registered member shareholdings (Form NAR1 / Section 627), and Ultimate Beneficial Ownership (UBO / SCR under Part 12 Division 2A) are verified through official statutory filing retrieval.

Pursuant to the Companies Ordinance (Cap. 622), statutory filings delivered by Magnum (Investment) Pharmaceutical Corporation Limited—such as Incorporation Forms (Form NNC1), Annual Returns (Form NAR1 under Section 662), and notices of director or registered office changes (Form ND2A / Form NR1)—are maintained by the Hong Kong Companies Registry. Where online electronic image indexing is pending synchronization or involves early historical microfiche archives, manual statutory retrieval from the Companies Registry can be commissioned through our compliance team.

According to multi-dimensional checks across Hong Kong statutory authorities: 1. Regulatory Licences: Officially licensed by Hong Kong statutory authorities, currently holding: Department of Health (DH Licensed Dealer) (Licence No. 645/3A/2019); 2. Judicial Screening (Litigation & Winding-Up): cross-referenced with the Hong Kong Judiciary public writs database and Official Receiver's Office (ORO) registers; no public civil action writs (HCA/DCCJ) or compulsory winding-up petitions (HCCW under Cap. 32) were found on current index records.

The statutory registered office of Magnum (Investment) Pharmaceutical Corporation Limited on official record is situated at: [ROOM 28, G/F, BLOCK I, KWAN YICK BUILDING, 432 DES VOEUX ROAD WEST, CENTRAL & WESTERN DISTRICT, HONG KONG]. Pursuant to Section 658 of the Companies Ordinance (Cap. 622), every Hong Kong company must maintain a registered office in Hong Kong to which all communications and legal notices may be addressed, and file Form NR1 within 15 days of any address change. Under Section 3 of the Companies (Disclosure of Company Name and Liability Status) Regulation (Cap. 622B), the company must continuously display its registered name in legible characters at its registered office.

Under Section 127 of the Companies Ordinance (Cap. 622), Hong Kong has abolished the mandatory use of a metallic common seal; Magnum (Investment) Pharmaceutical Corporation Limited (CRN: 2843147 / 8-digit BRN: 70859556) may lawfully execute a commercial contract without a common seal by having the document signed on its behalf by its sole director (for a single-director company) or by two directors / one director and the company secretary, and under Cap. 622B Section 4 must state its registered legal name on all contracts, transaction instruments, and official websites. Because commercial rubber chops are not registered with the Hong Kong Government, counterparties must retrieve the latest Annual Return (Form NAR1), director change notices (Form ND2A), and Register of Charges filings (Form NM1 under Cap. 622 s.334) from the Companies Registry to verify authorized signatory directors and asset pledges.